CTOs on the Move

Protea Biosciences

www.proteabio.com

 
Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.proteabio.com
  • 955 Hartman Run Rd Ste 210
    Morgantown, WV USA 26505
  • Phone: 304.292.2226

Executives

Name Title Contact Details

Similar Companies

Elucida Oncology

Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.

Voluntis

At the forefront of the medical and digital revolutions, Voluntis is a pioneer of digital therapeutics. We design prescription applications that embed medical intelligence in the smartphones of people suffering from chronic and rare diseases. By using our software, patients leverage their health data to simplify their medical care. Treatment is personalized, doctors and patients are connected to coordinate care and real-world outcomes are improved. Harnessing its proprietary technology, Voluntis has developed digital solutions for diabetes, respiratory diseases, cancer, anticoagulation and hemophilia. Whether in our French or US offices, we are always on the look out for talent that is passionate about digital technologies and changing patients`​ lives.

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.